GILEAD SCIENCES, INC.
GILEAD SCIENCES, INC. (GILD): 39 pipeline candidates · 6 upcoming catalysts · ~12 mo cash runway · 15 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
11.6 months
1% dilution
Lead: Approved
39 candidates
6 upcoming, next in ~256d
0 buys · 30 sells (180d)
A transparent, data-derived signal for GILEAD SCIENCES, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$155.1B
Cash
$7.6B
Quarterly Burn
$2.8B
Runway
11.6 mo
Revenue
$7.0B
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (39 candidates)
| Drug | Phase |
|---|---|
| anitocabtagene autoleucel | Phase 3 |
| atv | Phase 2/Phase 3 |
| axicabtagene ciloleucel | Phase 3 |
| b/f/taf | Phase 1 |
| bictegravir/emtricitabine/tenofovir alafenamide | Phase 2/Phase 3 |
| bulevirtide | BLA Filed |
| cayston | Approved |
| cobicistat tos | Phase 2/Phase 3 |
| denikitug | Phase 2 |
| domvanalimab | Phase 2 |
Showing 10 of 39 candidates. Sign up for full pipeline.
Upcoming Catalysts (6)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
2,297
Total value held
$139.64B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 161,309,552 | $22.48B |
| blackrock, inc. | 119,010,973 | $16.59B |
| fmr llc | 71,906,290 | $10.02B |
| state street corp | 59,858,585 | $8.34B |
| vanguard portfolio management llc | 35,129,465 | $4.90B |
| geode capital management, llc | 29,726,052 | $4.14B |
| dodge & cox | 24,250,826 | $3.38B |
| morgan stanley | 23,299,295 | $3.25B |
| bank of america corp /de/ | 19,978,936 | $2.78B |
| invesco ltd. | 15,526,336 | $2.16B |
Showing top 10 of 2,297 institutional holders of GILEAD SCIENCES, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in GILEAD SCIENCES, INC.'s pipeline?
GILEAD SCIENCES, INC. (GILD) has 39 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is GILEAD SCIENCES, INC.'s lead drug candidate?
GILEAD SCIENCES, INC.'s most advanced tracked candidate is anitocabtagene autoleucel (Phase 3) for Relapsed and/or refractory multiple myeloma in patients who have received one to three prior lines of therapy.
What is GILEAD SCIENCES, INC.'s next catalyst?
GILEAD SCIENCES, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, an" — expected March 1, 2027.
What is GILEAD SCIENCES, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, GILEAD SCIENCES, INC. has approximately 11.6 months of cash runway.
What is GILEAD SCIENCES, INC.'s market capitalization?
GILEAD SCIENCES, INC.'s market capitalization is approximately $155.1B.
Get the full picture on GILEAD SCIENCES, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.